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SELECTION OF THE MONTH 
Big Title: Something about Liver Transplantation as a tribute to Thomas Starzl 
 
Small titles:  
Early initiation of supplementary milk during breastfeeding increases the risk 
of NAFLD in adolescents. 
Intrahepatic myeloid cells drive liver inflammation 
Visualization of HEV RNA and proteins in human livers 
Cirrhosis: Should MELD be uncapped? 
 
ACUTE LIVER INFLAMMATION 
Paradoxical effects of interleukin-10 promoting acute liver immunopathology  
Besides secreting pro-inflammatory cytokines, chemokines and effector molecules, 
effector CD8+ T cells that arise upon acute infection with certain viruses have been 
shown to produce the anti-inflammatory cytokine interleukin (IL)-10 (a class 2 α-
helical cytokine, whose initial name was cytokine synthesis inhibitory factor [CSIF]), 
containing immunopathology. Whether the same occurs during acute hepatitis B 
virus (HBV) infection and the role that IL-10 might play in liver disease is currently 
unknown. Fioravanti et al. addressed this question using mouse models of HBV 
pathogenesis. They reveal that the IL-10 produced by effector CD8+ T cells 
promoted their own intrahepatic survival and, thus, supported, rather than 
suppressed, liver immunopathology. Studies should now investigate whether 
these findings (which challenge our traditional view of IL-10) are also observed with 
other infections in the liver and in other organs.  
 
IRON OVERLOAD 
Non-invasive assessment of liver iron  
Accumulation of liver iron is an independent factor of survival and carcinogenesis in 
various chronic liver diseases. Mueller et al. evaluated the ability of a novel room-
temperature susceptometer (RTS) to noninvasively assess liver iron concentration 
(LIC) in a prospective cohort of 264 patients with or without signs of iron overload or 
liver disease. They show that RTS allows the rapid and non-invasive 
measurement of liver iron. In comparison to magnetic resonance imaging, RTS 
could be a cost-effective bedside method for liver iron screening. 
 
ALCOHOLIC AND NON-ALCOHOLIC STEATOHEPATITIS 
Early detection of “high risk” alcohol consumption, influence of maternal 
obesity and early initiation of supplementary milk on adolescent NAFLD, use 
of CAP to detect fatty liver. 
Many patients with advance alcoholic liver disease have previous history of recurrent 
admissions to hospital, representing missed opportunities for intervention. Westwood 
et al. screened admissions to a major hospital to identify patients at increasing risk of 
alcohol harm. Patients with alcohol misuse were referred for either brief intervention 
or assessment by an alcohol specialist nurse. Out of 48,211 admissions that 
completed alcohol screening, 2.3% were classified at "increasing", and 4.0% at 
"high" risk of alcohol harm. High risk patients had more admissions in the 
previous three years and more emergency department attendances. Importantly, 
high risk patients had distinct diagnostic profiles in the admissions, including 
liver disease-related hospitalizations. This important study suggests that early 
identification and counseling in patients with hazardous alcohol intake could prevent 
hospitalization due to alcohol-induced organ damage.  
The prevalence of NAFLD in adolescent is increasing worldwide. Identifying early 
events leading to increased risk to develop NAFLF is critical to implementing health 
policy measures. There is inadequate knowledge regarding associations between 
infant nutrition and subsequent NAFLD. In this issue of the Journal, Ayonrinde et al. 
examined the association of maternal factors and infant nutrition, with the 
subsequent diagnosis of NAFLD in adolescents in Australia. NAFLD was 
diagnosed in 15% of the 1,170 adolescents examined. Breastfeeding without 
supplementary milk ≥6 months, maternal pre-pregnancy obesity and 
adolescent obesity were associated with NAFLD independent of a Western 
dietary pattern at age 17 years. Supplementary milk intake starting before 6 months 
was associated with a higher prevalence and ultrasound severity of NAFLD. This 
relevant study suggests that maternal obesity and early initiation of 
supplementary mils increases the risk of NAFLD at young ages.  
Besides epidemiological studies, another paper in this issue investigated the 
diagnosis of NAFLD. Non-invasive methods to diagnose fatty liver disease are 
increasingly used in clinical practice. Controlled attenuation parameter (CAP) can be 
performed together with liver stiffness measurement (LSM) by transient elastography 
to diagnose fatty liver. However, the validity criteria are not well defined. Wong et al. 
performed a large multicentric study in Europe and Hong Kong using CAP to 
estimate the presence of steatosis in patients undergoing a liver biopsy. The 
AUROC for CAP to diagnose fatty liver was more than 0.80 across the different 
cohorts. The accuracy of CAP in detecting grade 2 and 3 steatosis was lower among 
patients with body mass index ≥30 kg/m2 and F3-4 fibrosis. Importantly, the validity 
of CAP for the diagnosis of fatty liver was lower if the IQR of CAP is ≥40 dB/m. 
This study will be useful to establish the parameters for an accurate assessment of 
fatty live using the CAP technology 
 
HEPATITIS C VIRUS (HCV) INFECTION 
Estimating the consequences of alcohol use disorders in chronic hepatitis C, 
Apo-E-mediated HCV immune escape, KIR and HLA genetics contributes to 
HCV susceptibility, intrahepatic myeloid cells drive liver inflammation via 
activation of translocated intestinal bacterial products 
The inter-individually variable rate of disease progression is a well-recognized but 
poorly understood feature of chronic hepatitis C virus (HCV) infection. Alcohol use 
disorders – often associated with HCV infection – may accelerate the disease course 
but the extent to which alcohol contributes to the HCV-associated disease burden 
has not been carefully explored yet. In a French nationwide study, Schwarzinger et 
al. tracked liver-related complications and mortality over a 5-year period in 97,347 
young and middle-aged patients with chronic HCV infection according to the 
presence or absence of alcohol use disorders. The most prominent findings of 
this provocative study were that alcohol use disorders might contribute to 
more than two-thirds of all liver transplantations, and liver deaths recorded in 
patients with chronic HCV infection but also that alcohol rehabilitation and 
abstinence will be associated with a 50% risk reductions of liver-related 
complications. This important study supports the promotion of alcohol abstinence 
and rehabilitation programs to reduce HCV-related complications. 
HCV replication is linked to host factors and cellular pathways involved in lipid 
metabolism like apolipoproteins (Apo) -E and C-I facilitating infection by increasing 
virus attachment or membrane fusion, respectively. Little is known, however, about 
particle maturation processes outside of the virus producing cells including their 
impact for cell entry and immune evasion. Bankwitz et al. now report on a role of 
secreted Apo-E in ensuring the propagation of HCV in an environment with 
potentially neutralizing antibodies, and that the Apo-E-HCV interaction might be a 
crucial step to shield the virus particles from neutralizing antibodies. This 
elegant study further improves our understanding of HCV-Apo-E interaction and viral 
immune escape mechanisms which may guide the pathway towards a prophylactic 
HCV vaccine. 
Natural killer (NK) cell function may be critically involved in protection from infection 
prior to seroconversion but also resolution of acute hepatitis C. Killer-cell 
immunoglobulin-like receptors (KIRs) on NK cells interact with human leukocyte 
antigen (HLA) class I molecules on infected cells resulting in NK cell activation or 
inhibition. In order to further elucidate potential mechanisms of protective immunity 
against HCV, genetically determined combinations of KIR and KIR-ligands on the 
outcome of HCV infection were studied by Thoens C et al. in individuals with high-
risk behavior for HCV infection, i.e., persons who inject drugs (PWID). Whereas the 
presence of a KIR3DL1/HLA-Bw4-80T genotype was associated with 
spontaneous clearance of HCV infection, a protective state against primary 
infection was mediated by HLA-Bw4 alleles. These data suggest that superior 
functionality of NK cells against HCV plays an important mechanistic role for the 
advantageous effect of high HLA-Bw4 copy numbers and the KIR3DL1/HLA-Bw4-
80T genotype on the natural outcome of HCV infection. 
Monocytes and macrophages form a heterogeneous population of myeloid cells 
which have been recently recognized as important players in promoting 
angiogenesis, liver fibrosis and HCC development. Tan-Garcia et al. defined the 
contribution of intrahepatic CD14+ myeloid cells to chronic liver inflammation in 
patients with viral-related end-stage liver disease. Activated myeloid cells 
(particularly CD14+HLA-DRhiCD206+ cells) which spontaneously produced pro-
inflammatory mediators were enriched in advanced viral-induced liver disease, 
and showed enhanced responses to bacterial product stimulation. The 
intriguing findings that treatment with oral antibiotics normalized intrahepatic 
CD14+HLA-DRhiCD206+ myeloid cell numbers may indicate that liver inflammation 
can be sustained by a pathogenic gut-liver interaction but also implies to give 
microbiome-modifying or myeloid-depleting therapies greater considerations in 
advanced liver disease. 
 
HEPATITIS E VIRUS (HEV) INFECTION 
Visualization HEV RNA and proteins in human livers 
Hepatitis E virus infection gathered increasing interest as the most common cause of 
acute viral hepatitis worldwide and a pathogen associated with a large number of 
extrahepatic manifestations but also chronic liver disease in immunosuppressed 
patients. Yet, accurate serologic and histopathologic diagnosis of HEV infection is 
challenging. Lenggenhager et al. systematically evaluated immunohistochemistry 
(IHC) and in situ hybridization (ISH) for visualizing HEV proteins and RNA in cell 
lines and human liver tissues, and determined the value of these tools in a diagnostic 
setting. They showed that HEV ORF2 protein can be taken as a robust marker for 
tissue-based diagnostics but also described for the first time a subcellular 
distribution pattern of the ORF2 protein including a nuclear localization which 
suggest a redistribution of the virus during infection. Precise knowledge of the 
temporal and spatial viral distribution in the liver during infection would not only be of 
advantage for developing tissue-based diagnostics, but is also a prerequisite for a 
better understanding of HEV pathogenesis. 
 
PRIMARY SCLEROSING CHOLANGITIS 
norURSO: A novel strategy to treat PSC 
The treatment of PSC is an unmet medical need. 24-norursodeoxycholic acid is an 
analogue of UDCA that has been shown to have anti-fibrotic and anti-inflammatory 
effect in animal models. In a vital study, Fickert et al. performed a large dose 
ranging, placebo-controlled clinical trial of norURSO in patients with PSC. They 
showed that all the doses were safe, well-tolerated and significantly reduced 
serum alkaline phosphatase and others markers of liver injury justifying a 
Phase 3 trial of norURSO in PSC patients. 
 
SPLANCHNIC VEIN THROMBOSIS 
Prediction of presence of calreticulin gene (CALR) mutation 
Splanchnic vein thrombosis (SVT) is associated with myeloproliferative neoplasm 
and JAK mutations in about 80-90% patients. CALR mutations are found in only 2% 
cases. At present it is not clear which patients should be tested for this mutation. In a 
large prospective study, Rautou et al. showed that CALR mutation was likely 
to be present in the patients with SVT that were negative for the JAK mutation, 
had a spleen size of more than 16 cm and a platelet count of more than 200 x 
109/L. They validated these criteria in an independent cohort and the application of 
this strategy would reduce the need for CALR testing by 96%. 
 
TIPS AND HEPATIC ENCEPHALOPATHY 
8mm covered shunts reduces the risk of hepatic encephalopathy (HE) 
The occurrence of HE is a devastating complication of TIPS and current strategies 
fail to identify patients at risk. Wang et al. performed a very important, large 
randomized clinical trial comparing 8mm stents versus 10mm stents. The data show 
that shunt insufficiency was similar between the groups but the risk of HE was 
significantly lower in the patients receiving the 8 mm stents compared with the 
patients receiving the 10 mm stents. The 47% risk reduction in the occurrence of 
HE argues strongly for the routine use of the 8mm shunts for TIPS. 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Predicting microvascular invasion 
Microvascular invasion (MVI) of HCC is a major risk factor for early recurrence within 
the first 2 years after curative treatment. Although macrovascular invasion can be 
frequently detected prior to surgery by complementary imaging modalities including 
computed tomography and magnetic resonance imaging, MVI can rarely be 
determined preoperatively because it is a histopathological diagnosis. It is therefore 
of great importance to identify preoperative imaging biomarkers for predicting MVI. 
Here, Lee et al. report the results of a study aimed to identify preoperative magnetic 
resonance imaging biomarkers for predicting MVI, determine their diagnostic 
performance, and evaluate whether they are associated with early recurrence after 
surgery for single HCC. They reveal that a combination of two or more among 
arterial peritumoral enhancement, non-smooth tumor margin, and peritumoral 
hypointensity on hepatobiliary phase can be used as a preoperative imaging 
biomarker for predicting MVI with a specificity of more than 90%. Combination 
of these criteria is associated with early recurrence after surgery of single HCC. 
 
LIVER TRANSPLANTATION 
Rationale for uncapping the MELD score 
Assigning priority for liver transplantation using the MELD score has made the 
distribution of organs more equitable. However, the MELD score is capped at 40, 
which means that although the patients with a MELD score of more than 40 have a 
higher mortality, these patients do not have priority for liver transplantation. Mitra et 
al. performed an important study using the data from the UNOS database and 
showed that the patients with a MELD score of more than 40 had a 
significantly higher risk of death within 30 days but the 1- and 3-year survival 
rates with transplantation were similar. The data argue strongly for uncapping the 
MELD score.  
 
